SURMODICS INC Form 10-Q August 01, 2014 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

Commission File Number: 0-23837

SurModics, Inc.

(Exact name of registrant as specified in its charter)

MINNESOTA (State of

41-1356149 (I.R.S. Employer

incorporation)

Identification No.)

9924 West 74th Street

Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (952) 500-7000

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer "

Accelerated filer

X

Non-accelerated filer " (Do not check if a smaller reporting company) Smaller reporting company " Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No x

The number of shares of the registrant s Common Stock, \$.05 par value per share, outstanding as of July 31, 2014 was 13,596,744.

TABLE OF CONTENTS

PART I	<u>. FINANCIAL INFORMATION</u>	3
Item 1.	Financial Statements	3
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	29
PART I	I. OTHER INFORMATION	30
Item 1.	<u>Legal Proceedings</u>	30
Item 1A	. Risk Factors	30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3.	Defaults Upon Senior Securities	30
Item 4.	Mine Safety Disclosures	30
Item 5.	Other Information	30
Item 6.	<u>Exhibits</u>	31
SIGNA'	<u>rures</u>	
EX-12		
EX-31.1		
EX-31.2		
EX-32.1		
EX-32.2		
EX-101	INSTANCE DOCUMENT	
EX-101	SCHEMA DOCUMENT	
EX-101	CALCULATION LINKBASE DOCUMENT	
EX-101	DEFINITION LINKBASE DOCUMENT	
EX-101	LABEL LINKBASE DOCUMENT	
EX-101	PRESENTATION LINKBASE DOCUMENT	

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

SurModics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)	June 30, 2014 (Unc	September 30, 2013 audited)		
ASSETS				
Current Assets:				
Cash and cash equivalents	\$ 39,729	\$ 15,495		
Available-for-sale securities	882	10,212		
Accounts receivable, net of allowance for doubtful accounts of \$53 and \$26 as of				
June 30, 2014 and September 30, 2013, respectively	5,176	5,332		
Inventories	2,900	3,328		
Deferred tax assets	321	506		
Prepaids and other	1,718	860		
Current assets of discontinued operations	85	46		
Total Current Assets	50,811	35,779		
Property and equipment, net	12,710	12,845		
Available-for-sale securities	16,497	32,397		
Deferred tax assets	6,392	6,038		
Intangible assets, net	3,131	3,688		
Goodwill	8,010	8,010		
Other assets, net	3,166	3,166		
Total Assets	\$ 100,717	\$ 101,923		
LIABILITIES AND STOCKHOLDERS EQUITY				
Current Liabilities:				
Accounts payable	\$ 1,400	\$ 954		
Accrued liabilities:				
Compensation	1,756	2,271		
Accrued other	844	1,149		
Share repurchase accrual		1,004		
Deferred revenue	41	43		
Restructuring and other current liabilities	2	416		
Current liabilities of discontinued operations	75	139		
Total Current Liabilities	4,118	5,976		
Deferred revenue, less current portion	149	160		
Other long-term liabilities	1,779	1,970		

Edgar Filing: SURMODICS INC - Form 10-Q

Total Liabilities	6,046	8,106
Commitments and Contingencies (Note 17)		
Stockholders Equity:		
Series A Preferred stock- \$.05 par value, 450,000 shares authorized; no shares issued and		
outstanding		
Common stock- \$.05 par value, 45,000,000 shares authorized; 13,594,564 and		
13,891,402 shares issued and outstanding, respectively	680	695
Additional paid-in capital	2,419	2,028
Accumulated other comprehensive income	36	58
Retained earnings	91,536	91,036
Total Stockholders Equity	94,671	93,817
Total Liabilities and Stockholders Equity	\$ 100,717	\$ 101,923

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

SurModics, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(In thousands, except per share data)	Three M End June 2014 (Unau	led 200, 2013	Enc June 2014	line Months Ended June 30, 14 2013 Unaudited)			
Revenue:	ф 7.20 <i>5</i>	¢ 7.027	¢ 22 170	¢ 22 204			
Royalties and license fees Product sales	\$ 7,385 6,067	\$ 7,827	\$ 22,179	\$ 22,294			
		5,577 885	16,632 3,292	16,688			
Research and development	1,164	003	3,292	2,853			
Total revenue	14,616	14,289	42,103	41,835			
Operating costs and expenses:							
Product costs	2,037	1,990	5,737	5,894			
Research and development	3,655	4,009	11,488	11,145			
Selling, general and administrative	3,591	4,052	11,736	11,552			
Total operating costs and expenses	9,283	10,051	28,961	28,591			
Operating income from continuing operations	5,333	4,238	13,142	13,244			
Other income (loss):							
Investment income, net	42	60	194	187			
Impairment loss on strategic investment	20		700	(129)			
Gain on sales of strategic investments	28	2	709	119			
Other income, net		2	125	1,341			
Other income, net	70	62	1,028	1,518			
Income from continuing operations before income taxes	5,403	4,300	14,170	14,762			
Income tax provision	(1,729)	(1,122)	(4,407)	(3,916)			
Income from continuing operations	3,674	3,178	9,763	10,846			
(Loss) income from discontinued operations, net of income taxes	(76)	(47)	(76)	635			
Net income	\$ 3,598	\$ 3,131	\$ 9,687	\$ 11,481			
Basic income (loss) per share:							
Continuing operations	\$ 0.27	\$ 0.22	\$ 0.72	\$ 0.74			
Discontinued operations	(0.01)	0.00	(0.01)	0.04			
Net income	\$ 0.26	\$ 0.22	\$ 0.71	\$ 0.79			
Diluted income (loss) per share:							

Edgar Filing: SURMODICS INC - Form 10-Q

Continuing operations	\$	0.27	\$	0.22	\$	0.70	\$	0.73
Discontinued operations		(0.01)		0.00		(0.01)		0.04
Net income	\$	0.26	\$	0.21	\$	0.70	\$	0.77
Weighted average number of shares outstanding:								
Basic	1	3,585	1	14,413	1	13,639	1	14,563
Diluted	1	3,813	1	14,739	1	13,891	1	14,823

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

SurModics, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

	Three Months Ended June 30,				Nine Months Ended June 30,		
		2014		2013	2014	2013	
(In thousands)	(Unaudited)			<i>d</i>)	(Unaudited)		
Net income	\$	3,598	\$	3,131	\$ 9,687	\$11,481	
Other comprehensive income (loss), net of tax:							
Unrealized holding gains (losses) on available-for-sale securities							
arising during the period		46		(158)	62	158	
Reclassification adjustment for realized gains included in net income				(1)	(84)	(230)	
Other comprehensive income (loss)		46		(159)	(22)	(72)	
Comprehensive income	\$	3,644	\$	2,972	\$ 9,665	\$11,409	

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

SurModics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)	Nine Months Ended June 30, 2014 2013 (Unaudited)		
Operating Activities:	(Chan		
Net income	\$ 9,687	\$ 11,481	
Adjustments to reconcile net income to net cash provided by operating activities from	Ψ 2,007	Ψ 11,101	
continuing operations:			
Loss (income) from discontinued operations	76	(635)	
Depreciation and amortization	2,054	2,174	
Stock-based compensation	3,043	1,983	
Deferred taxes	(98)	34	
Gain on sales of available-for-sale securities and strategic investments	(835)	(1,460)	
Impairment loss on investments	, ,	129	
Excess tax (benefit) deficiency from stock-based compensation plans	(452)	252	
Change in operating assets and liabilities, excluding the impact from discontinued	,		
operations:			
Accounts receivable	156	333	
Inventories	428	314	
Prepaids and other	(114)	(305)	
Accounts payable and accrued liabilities	(919)	(876)	
Income taxes	(560)	(1,520)	
Net cash provided by operating activities from continuing operations	12,466	11,904	
Investing Activities:			
Purchases of property and equipment	(1,165)	(1,448)	
Purchases of available-for-sale securities	(132,648)	(34,599)	
Sales and maturities of available-for-sale securities	157,970	34,487	
Cash received from sales of strategic investments	708	2,286	
Cash transferred to discontinued operations	(239)	(118)	
Net cash provided by investing activities from continuing operations	24,626	608	
Financing Activities:			
Excess tax benefit (deficiency) from stock-based compensation plans	452	(252)	
Issuance of common stock	348	273	
Repurchase of common stock	(12,544)	(10,323)	
Purchase of common stock to pay employee taxes	(1,114)	(39)	
Net cash used in financing activities from continuing operations	(12,858)	(10,341)	

Net cash provided by continuing operations

24,234

2,171

Discontinued Operations:

Net cash used in